Sihuan Pharmaceutical Holdings Group Ltd
HKEX:460
Sihuan Pharmaceutical Holdings Group Ltd
HKEX:460
Price:
1.42
HKD
-0.7%
Market Closed
Market Cap:
HK$13.1B
Relative Value
The Relative Value of one
Sihuan Pharmaceutical Holdings Group Ltd
stock under the Base Case scenario is
0.48
HKD.
Compared to the current market price of 1.42 HKD,
Sihuan Pharmaceutical Holdings Group Ltd
is
Overvalued by 66%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
0.48
HKD
Overvaluation 66%
Multiples Across Competitors
Competitors Multiples
Sihuan Pharmaceutical Holdings Group Ltd Competitors
Sihuan Pharmaceutical Holdings Group Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
|
Sihuan Pharmaceutical Holdings Group Ltd
HKEX:460
|
13.1B HKD | 5.5 | -142.4 | 108.8 | -55.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
879B USD | 13.5 | 42.6 | 28.8 | 30.7 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
576.7B USD | 6.1 | 21.5 | 15 | 18.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
256.6B CHF | 4.2 | 19.9 | 11.8 | 13.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
233.8B CHF | 5.4 | 21.6 | 13.3 | 17.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
222.9B GBP | 5.1 | 29.2 | 16.2 | 22.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
286.7B USD | 4.4 | 15.7 | 9.7 | 11.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 11 | 8.1 | 9.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
154.3B USD | 2.5 | 19.9 | 7.7 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
121.9B USD | 2.5 | 17.3 | 7.3 | 8.9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
